Alkermes: A More Than Solid Quarter

Alkermes plc (ALKS) reported Q2 results that surpassed consensus, delivering GAAP EPS of $0.52 (double expectations) and revenue of $390.7 million, despite a 2% year-over-year decline primarily due to non-recurring prior-period royalties. The company emphasized strong growth in its core proprietary products (VIVITROL, ARISTADA, LYBALVI) and issued encouraging FY2025 sales guidance for these therapies. With a robust balance sheet including $1.05 billion in cash and no long-term debt, an active $200 million share repurchase program, and a promising narcolepsy candidate in Phase 2 trials, analysts largely maintained Buy ratings, citing the company's solid financial health and pipeline advancements.

Analysis

Alkermes plc reported a robust second quarter, delivering GAAP earnings of $0.52 per share, which was more than double consensus expectations. While total revenues declined 2% year-over-year to $390.7 million, this figure substantially beat forecasts by over $45 million. The top-line decline is attributable to a sharp drop in 'Other royalties', which were inflated in the prior-year period by non-recurring back payments for INVEGA® products. Critically, the company's core commercial portfolio demonstrated strength, with solid revenue growth across its three primary products: LYBALVI, ARISTADA, and VIVITROL. Management issued encouraging full-year 2025 sales guidance for these drugs, projecting combined revenues between $1.1 billion and $1.16 billion. The company's financial position is exceptionally strong, ending the quarter with $1.05 billion in cash and marketable securities, no long-term debt, and an active $200 million share repurchase authorization. A key forward-looking catalyst is the narcolepsy candidate ALKS 2680, with data from three Phase 2 studies anticipated before year-end. Despite the strong quarter, analyst consensus projects an earnings decline in FY2025, reflecting the loss of prior non-recurring revenue, and estimates for FY2026 show significant variance, indicating uncertainty in the outer years.

Key Decisions for Investors

• Given the strong operational performance, a cash-rich balance sheet, and a valuation below 10x trailing earnings, investors may find the current share price an attractive entry point, supported by the ongoing stock repurchase program.
• Investors should closely monitor for the release of Phase 2 data for the narcolepsy candidate ALKS 2680 before year-end, as this is the most significant near-term catalyst with the potential to materially impact the stock's valuation.
• It is prudent to track the revenue growth of the core products (LYBALVI, ARISTADA, VIVITROL) against guidance to ensure they can offset the normalization of royalty income, as this will be key to challenging the consensus forecast for a profit decline in FY2025.
• The 7% short interest and wide variance in out-year earnings estimates warrant attention, suggesting that while fundamentals appear solid, a segment of the market remains skeptical of the company's long-term growth trajectory post-royalty normalization.